Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 37,410 shares at $113.58 ($4.3M) on 2020-06-18, disclosed to the SEC on 2020-06-22.
Seasonal sale ($4.3M) by Director — this insider has traded RGEN in June in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $113.58 | 2,677 | $304K | 7.1% |
| 2 | $113.58 | 2,677 | $304K | 7.1% |
| 3 | $114.49 | 5,243 | $600K | 13.9% |
| 4 | $114.49 | 5,243 | $600K | 13.9% |
| 5 | $115.76 | 8,217 | $951K | 22.1% |
| 6 | $115.76 | 8,217 |
| $951K |
| 22.1% |
| 7 | $116.56 | 2,568 | $299K | 6.9% |
| 8 | $116.56 | 2,568 | $299K | 6.9% |
| Total | $115.20 avg | 37,410 | $4.3M | 100% |
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |